Cargando…

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis

MicroRNAs regulate bone homeostasis, and circulating microRNAs have been proposed as novel bone biomarkers. The effect of anti‐osteoporotic treatment on circulating microRNAs has not been described in detail. Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigl, Moritz, Kocijan, Roland, Ferguson, James, Leinfellner, Gabriele, Heimel, Patrick, Feichtinger, Xaver, Pietschmann, Peter, Grillari, Johannes, Zwerina, Jochen, Redl, Heinz, Hackl, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252367/
https://www.ncbi.nlm.nih.gov/pubmed/33598975
http://dx.doi.org/10.1002/jbmr.4276
_version_ 1783717284471111680
author Weigl, Moritz
Kocijan, Roland
Ferguson, James
Leinfellner, Gabriele
Heimel, Patrick
Feichtinger, Xaver
Pietschmann, Peter
Grillari, Johannes
Zwerina, Jochen
Redl, Heinz
Hackl, Matthias
author_facet Weigl, Moritz
Kocijan, Roland
Ferguson, James
Leinfellner, Gabriele
Heimel, Patrick
Feichtinger, Xaver
Pietschmann, Peter
Grillari, Johannes
Zwerina, Jochen
Redl, Heinz
Hackl, Matthias
author_sort Weigl, Moritz
collection PubMed
description MicroRNAs regulate bone homeostasis, and circulating microRNAs have been proposed as novel bone biomarkers. The effect of anti‐osteoporotic treatment on circulating microRNAs has not been described in detail. Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham‐operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment. Forty‐two Sprague Dawley rats underwent SHAM surgery (n = 10) or ovariectomy (n = 32). After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10). Serum samples were collected at weeks 8, 12, 16, and 20 after surgery. A total of 91 microRNAs were analyzed by RT‐qPCR in serum samples collected at week 20. Based on the results, 29 microRNAs were selected for longitudinal analysis at all four study time points. Changes in bone mineral density and microstructure were followed up by in vivo micro‐CT and ex vivo nano‐CT. Ovariectomy resulted in the loss of trabecular bone, which was reversed by osteoanabolic and antiresorptive treatment. Differential expression analysis identified 11 circulating miRNAs that were significantly regulated after treatment. For example, miR‐107 and miR‐31‐5p increased in vehicle‐treated OVX animals, whereas they decreased during teriparatide treatment. Additional miRNAs were identified that showed significant correlations to bone microstructure or bone miRNA expression, including miR‐203a‐3p, which exhibited a significant negative correlation to vertebral and tibial trabecular bone volume fraction (%). Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR‐34a‐5p, miR‐31‐5p, miR‐30d‐3p, miR‐378a‐5p) or teriparatide treatment only (miR‐375‐3p, miR‐183‐5p, miR‐203a‐3p, miR‐203b‐3p). Gene target network analysis identified WNT and Notch signaling as the main signaling pathways controlled by these miRNAs. Thus, ovariectomy results in time‐dependent deregulation of circulating miRNAs compared with SHAM animals. Anti‐osteoporotic treatments can rescue this effect, showing that bone‐related miRNAs might act as novel biomarkers for treatment monitoring. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
format Online
Article
Text
id pubmed-8252367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-82523672021-07-07 Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis Weigl, Moritz Kocijan, Roland Ferguson, James Leinfellner, Gabriele Heimel, Patrick Feichtinger, Xaver Pietschmann, Peter Grillari, Johannes Zwerina, Jochen Redl, Heinz Hackl, Matthias J Bone Miner Res Original Articles MicroRNAs regulate bone homeostasis, and circulating microRNAs have been proposed as novel bone biomarkers. The effect of anti‐osteoporotic treatment on circulating microRNAs has not been described in detail. Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham‐operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment. Forty‐two Sprague Dawley rats underwent SHAM surgery (n = 10) or ovariectomy (n = 32). After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10). Serum samples were collected at weeks 8, 12, 16, and 20 after surgery. A total of 91 microRNAs were analyzed by RT‐qPCR in serum samples collected at week 20. Based on the results, 29 microRNAs were selected for longitudinal analysis at all four study time points. Changes in bone mineral density and microstructure were followed up by in vivo micro‐CT and ex vivo nano‐CT. Ovariectomy resulted in the loss of trabecular bone, which was reversed by osteoanabolic and antiresorptive treatment. Differential expression analysis identified 11 circulating miRNAs that were significantly regulated after treatment. For example, miR‐107 and miR‐31‐5p increased in vehicle‐treated OVX animals, whereas they decreased during teriparatide treatment. Additional miRNAs were identified that showed significant correlations to bone microstructure or bone miRNA expression, including miR‐203a‐3p, which exhibited a significant negative correlation to vertebral and tibial trabecular bone volume fraction (%). Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR‐34a‐5p, miR‐31‐5p, miR‐30d‐3p, miR‐378a‐5p) or teriparatide treatment only (miR‐375‐3p, miR‐183‐5p, miR‐203a‐3p, miR‐203b‐3p). Gene target network analysis identified WNT and Notch signaling as the main signaling pathways controlled by these miRNAs. Thus, ovariectomy results in time‐dependent deregulation of circulating miRNAs compared with SHAM animals. Anti‐osteoporotic treatments can rescue this effect, showing that bone‐related miRNAs might act as novel biomarkers for treatment monitoring. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). John Wiley & Sons, Inc. 2021-03-10 2021-06 /pmc/articles/PMC8252367/ /pubmed/33598975 http://dx.doi.org/10.1002/jbmr.4276 Text en © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Weigl, Moritz
Kocijan, Roland
Ferguson, James
Leinfellner, Gabriele
Heimel, Patrick
Feichtinger, Xaver
Pietschmann, Peter
Grillari, Johannes
Zwerina, Jochen
Redl, Heinz
Hackl, Matthias
Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title_full Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title_fullStr Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title_full_unstemmed Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title_short Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
title_sort longitudinal changes of circulating mirnas during bisphosphonate and teriparatide treatment in an animal model of postmenopausal osteoporosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252367/
https://www.ncbi.nlm.nih.gov/pubmed/33598975
http://dx.doi.org/10.1002/jbmr.4276
work_keys_str_mv AT weiglmoritz longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT kocijanroland longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT fergusonjames longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT leinfellnergabriele longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT heimelpatrick longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT feichtingerxaver longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT pietschmannpeter longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT grillarijohannes longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT zwerinajochen longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT redlheinz longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis
AT hacklmatthias longitudinalchangesofcirculatingmirnasduringbisphosphonateandteriparatidetreatmentinananimalmodelofpostmenopausalosteoporosis